Luke Adams

Luke Adams is a Research Fellow in Medicinal Chemistry at Monash University's Faculty of Pharmacy and Pharmaceutical Sciences. His academic profile indicates active research spanning structural biology, chemical biology, and drug discovery with a focus on advanced spectroscopic techniques.

His research interests center on NMR spectroscopy and protein-ligand interactions, with significant contributions to unnatural amino acid engineering and fragment-based drug design. Key methodologies include genetic encoding of silylated lysines, gadolinium-based EPR distance measurements, and photocaged probes for spatiotemporal control of protein function. His work bridges structural characterization with therapeutic development, particularly in epigenetic targets and enzyme mechanisms.

Analysis of his publication record (2002-2025) reveals consistent output in high-impact journals including Nature Communications, Journal of the American Chemical Society, and Journal of Medicinal Chemistry. His research demonstrates strong interdisciplinary integration across biophysics, medicinal chemistry, and chemical biology, with recent emphasis on neuroinflammatory targets and bromodomain inhibitors. The work contributes to UN Sustainable Development Goals related to health and well-being.

Laboratory work appears centered on protein engineering and spectroscopic methodology development, with collaborations spanning biochemistry, pharmacology, and structural biology groups at Monash University.